Annual CFO
$143.60 M
+$27.55 M+23.74%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual cash flow from operations is currently $143.60 million, with the most recent change of +$27.55 million (+23.74%) on 31 December 2023. During the last 3 years, it has risen by +$98.57 million (+218.87%). CPRX annual CFO is now at all-time high.CPRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$72.87 M
+$8.74 M+13.62%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly cash flow from operations is currently $72.87 million, with the most recent change of +$8.74 million (+13.62%) on 30 September 2024. Over the past year, it has increased by +$27.74 million (+61.48%). CPRX quarterly CFO is now at all-time high.CPRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$224.58 M
+$27.74 M+14.09%
30 September 2024
Summary:
Catalyst Pharmaceuticals TTM cash flow from operations is currently $224.58 million, with the most recent change of +$27.74 million (+14.09%) on 30 September 2024. Over the past year, it has increased by +$96.55 million (+75.41%). CPRX TTM CFO is now at all-time high.CPRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +23.7% | +61.5% | +75.4% |
| 3 y3 years | +218.9% | +235.7% | +313.6% |
| 5 y5 years | +649.2% | +348.1% | +1507.8% |
CPRX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +218.9% | at high | +759.5% | at high | +313.6% |
| 5 y | 5 years | at high | +649.2% | at high | +1810.6% | at high | +1507.8% |
| alltime | all time | at high | +649.2% | at high | +972.5% | at high | +899.7% |
Catalyst Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $72.87 M(+13.6%) | $224.58 M(+14.1%) |
| June 2024 | - | $64.14 M(+100.9%) | $196.84 M(+20.4%) |
| Mar 2024 | - | $31.93 M(-42.6%) | $163.46 M(+13.8%) |
| Dec 2023 | $143.60 M(+23.7%) | $55.65 M(+23.3%) | $143.60 M(+12.2%) |
| Sept 2023 | - | $45.13 M(+46.7%) | $128.03 M(+3.1%) |
| June 2023 | - | $30.75 M(+154.8%) | $124.20 M(+3.8%) |
| Mar 2023 | - | $12.07 M(-69.9%) | $119.64 M(+3.1%) |
| Dec 2022 | $116.05 M(+92.2%) | $40.08 M(-3.0%) | $116.05 M(+22.0%) |
| Sept 2022 | - | $41.30 M(+57.7%) | $95.15 M(+25.9%) |
| June 2022 | - | $26.19 M(+208.9%) | $75.55 M(+16.2%) |
| Mar 2022 | - | $8.48 M(-55.8%) | $65.04 M(+7.7%) |
| Dec 2021 | $60.37 M(+34.1%) | $19.18 M(-11.7%) | $60.37 M(+11.2%) |
| Sept 2021 | - | $21.71 M(+38.5%) | $54.30 M(+23.3%) |
| June 2021 | - | $15.68 M(+311.0%) | $44.05 M(+5.8%) |
| Mar 2021 | - | $3.81 M(-70.9%) | $41.63 M(-7.5%) |
| Dec 2020 | $45.03 M(+30.1%) | $13.11 M(+14.4%) | $45.03 M(+1.8%) |
| Sept 2020 | - | $11.45 M(-13.7%) | $44.22 M(-9.8%) |
| June 2020 | - | $13.27 M(+83.9%) | $49.03 M(-1.6%) |
| Mar 2020 | - | $7.21 M(-41.3%) | $49.84 M(+44.0%) |
| Dec 2019 | $34.61 M(-232.4%) | $12.29 M(-24.4%) | $34.61 M(+147.8%) |
| Sept 2019 | - | $16.26 M(+15.6%) | $13.97 M(-251.1%) |
| June 2019 | - | $14.07 M(-275.6%) | -$9.25 M(-67.1%) |
| Mar 2019 | - | -$8.02 M(-4.0%) | -$28.08 M(+7.4%) |
| Dec 2018 | -$26.15 M(+90.3%) | -$8.35 M(+20.1%) | -$26.15 M(+19.8%) |
| Sept 2018 | - | -$6.95 M(+46.0%) | -$21.83 M(+24.7%) |
| June 2018 | - | -$4.76 M(-21.7%) | -$17.51 M(+9.8%) |
| Mar 2018 | - | -$6.08 M(+50.9%) | -$15.95 M(+16.0%) |
| Dec 2017 | -$13.74 M(-23.5%) | -$4.03 M(+53.1%) | -$13.74 M(-2.7%) |
| Sept 2017 | - | -$2.63 M(-17.8%) | -$14.12 M(-4.4%) |
| June 2017 | - | -$3.20 M(-17.5%) | -$14.77 M(-7.2%) |
| Mar 2017 | - | -$3.88 M(-12.1%) | -$15.91 M(-11.4%) |
| Dec 2016 | -$17.96 M(-0.3%) | -$4.41 M(+34.6%) | -$17.96 M(-1.2%) |
| Sept 2016 | - | -$3.28 M(-24.5%) | -$18.18 M(-10.2%) |
| June 2016 | - | -$4.34 M(-26.8%) | -$20.25 M(+0.5%) |
| Mar 2016 | - | -$5.93 M(+28.0%) | -$20.15 M(+11.9%) |
| Dec 2015 | -$18.02 M | -$4.63 M(-13.3%) | -$18.02 M(+3.8%) |
| Sept 2015 | - | -$5.34 M(+25.8%) | -$17.36 M(+11.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | - | -$4.25 M(+11.9%) | -$15.57 M(+8.8%) |
| Mar 2015 | - | -$3.79 M(-4.6%) | -$14.31 M(+10.6%) |
| Dec 2014 | -$12.94 M(+31.0%) | -$3.98 M(+12.0%) | -$12.94 M(-1.1%) |
| Sept 2014 | - | -$3.55 M(+19.1%) | -$13.09 M(+16.7%) |
| June 2014 | - | -$2.98 M(+23.0%) | -$11.22 M(+11.7%) |
| Mar 2014 | - | -$2.42 M(-41.3%) | -$10.05 M(+1.8%) |
| Dec 2013 | -$9.88 M(+92.1%) | -$4.13 M(+145.3%) | -$9.88 M(+34.6%) |
| Sept 2013 | - | -$1.68 M(-7.1%) | -$7.34 M(+8.6%) |
| June 2013 | - | -$1.81 M(-19.4%) | -$6.76 M(+11.0%) |
| Mar 2013 | - | -$2.25 M(+41.1%) | -$6.09 M(+18.4%) |
| Dec 2012 | -$5.14 M(+3.1%) | -$1.59 M(+44.8%) | -$5.14 M(+3.1%) |
| Sept 2012 | - | -$1.10 M(-3.8%) | -$4.98 M(-3.0%) |
| June 2012 | - | -$1.14 M(-12.1%) | -$5.14 M(-5.8%) |
| Mar 2012 | - | -$1.30 M(-9.5%) | -$5.46 M(+9.4%) |
| Dec 2011 | -$4.99 M(+32.7%) | -$1.44 M(+14.8%) | -$4.99 M(+15.5%) |
| Sept 2011 | - | -$1.25 M(-14.4%) | -$4.32 M(+11.2%) |
| June 2011 | - | -$1.46 M(+76.0%) | -$3.88 M(+8.8%) |
| Mar 2011 | - | -$831.10 K(+8.0%) | -$3.57 M(-5.1%) |
| Dec 2010 | -$3.76 M(-51.1%) | -$769.20 K(-5.9%) | -$3.76 M(-1.6%) |
| Sept 2010 | - | -$817.30 K(-28.9%) | -$3.82 M(-12.3%) |
| June 2010 | - | -$1.15 M(+12.5%) | -$4.35 M(-25.8%) |
| Mar 2010 | - | -$1.02 M(+23.2%) | -$5.87 M(-23.6%) |
| Dec 2009 | -$7.68 M(-7.0%) | -$828.90 K(-38.7%) | -$7.68 M(-21.2%) |
| Sept 2009 | - | -$1.35 M(-49.2%) | -$9.75 M(-10.7%) |
| June 2009 | - | -$2.66 M(-6.1%) | -$10.92 M(+10.6%) |
| Mar 2009 | - | -$2.84 M(-2.2%) | -$9.87 M(+19.5%) |
| Dec 2008 | -$8.26 M(+86.7%) | -$2.90 M(+15.1%) | -$8.26 M(+31.3%) |
| Sept 2008 | - | -$2.52 M(+56.0%) | -$6.29 M(+41.0%) |
| June 2008 | - | -$1.62 M(+32.0%) | -$4.46 M(+4.2%) |
| Mar 2008 | - | -$1.22 M(+31.3%) | -$4.28 M(-3.2%) |
| Dec 2007 | -$4.42 M(+275.5%) | -$932.30 K(+34.7%) | -$4.42 M(+26.7%) |
| Sept 2007 | - | -$692.10 K(-51.8%) | -$3.49 M(+24.7%) |
| June 2007 | - | -$1.43 M(+5.1%) | -$2.80 M(+105.1%) |
| Mar 2007 | - | -$1.37 M | -$1.37 M |
| Dec 2006 | -$1.18 M(+158.8%) | - | - |
| Dec 2005 | -$455.40 K(+97.6%) | - | - |
| Dec 2004 | -$230.50 K | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual CFO year-on-year change?
- What is Catalyst Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly CFO year-on-year change?
- What is Catalyst Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM CFO year-on-year change?
What is Catalyst Pharmaceuticals annual cash flow from operations?
The current annual CFO of CPRX is $143.60 M
What is the all time high annual CFO for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual cash flow from operations is $143.60 M
What is Catalyst Pharmaceuticals annual CFO year-on-year change?
Over the past year, CPRX annual cash flow from operations has changed by +$27.55 M (+23.74%)
What is Catalyst Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of CPRX is $72.87 M
What is the all time high quarterly CFO for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly cash flow from operations is $72.87 M
What is Catalyst Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, CPRX quarterly cash flow from operations has changed by +$27.74 M (+61.48%)
What is Catalyst Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of CPRX is $224.58 M
What is the all time high TTM CFO for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM cash flow from operations is $224.58 M
What is Catalyst Pharmaceuticals TTM CFO year-on-year change?
Over the past year, CPRX TTM cash flow from operations has changed by +$96.55 M (+75.41%)